Senegal's medicines regulator, created by decree in April 2022. It registers medicines, licenses pharmaceutical establishments, oversees clinical trials and runs pharmacovigilance. WHO lists it at maturity level 3 for medicines and vaccines, announced in 2024.
Decree 2022-824 of 7 April 2022 created the Agence sénégalaise de Réglementation pharmaceutique and set its rules of organisation. Its stated mission is to carry out the regulatory functions of national pharmaceutical policy, control the pharmaceutical sector and enforce the laws on pharmacy, medicines and other health products, pharmaceutical establishments, medical biology laboratories, testing and calibration laboratories and clinical trials. Its director general is Dr Aïssatou Sougou. The coordinates are an approximate Dakar city point.
The agency sets out its work against WHO's Global Benchmarking Tool: marketing authorisation, vigilance, market surveillance and control, licensing of establishments, inspection, laboratory testing, clinical trial oversight, lot release for vaccines, and approval and oversight of blood products. WHO's list of regulators at maturity levels 3 and 4, dated August 2026, gives ARP maturity level 3 for medicines and vaccines (non-producing), announced in 2024. Its own site, read on 11 November 2026, carries the banner that Senegal is the first country of French-speaking Africa to reach maturity level 3; that ranking is ARP's claim, not WHO's. Adverse effects can be reported to it through the Med Safety app or its online form.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/